Cargando…

Breakthrough infection after three doses of COVID-19 mRNA vaccine in systemic autoimmune rheumatic diseases: two cases in patients on TNF inhibitor monotherapy

Detalles Bibliográficos
Autores principales:	Vanni, Kathleen MM, Patel, Naomi J, DiIorio, Michael, Kowalski, Emily, Qian, Grace, Cook, Claire E, Ritter, Susan Y, Wallace, Zachary S, Sparks, Jeffrey A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Infections
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8811273/ https://www.ncbi.nlm.nih.gov/pubmed/35110366 http://dx.doi.org/10.1136/rmdopen-2021-002082

Ejemplares similares

Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: From the first wave to Omicron
por: Kawano, Yumeko, et al.
Publicado: (2022)

Factors associated with COVID-19 breakthrough infection among vaccinated patients with rheumatic diseases: A cohort study
por: Patel, Naomi J., et al.
Publicado: (2023)

SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
por: Liew, Jean, et al.
Publicado: (2022)

Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study
por: Schiff, Abigail E., et al.
Publicado: (2023)

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
por: DiIorio, Michael, et al.
Publicado: (2022)

DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study
por: Di Iorio, Michael, et al.
Publicado: (2022)

Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: A retrospective cohort study
por: Qian, Grace, et al.
Publicado: (2022)

Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

404. Impact of cross-coronavirus humoral immunity in post-acute sequelae of COVID-19 in systemic autoimmune rheumatic diseases patients
por: Herman, Jonathan, et al.
Publicado: (2023)

Biotechnological Drugs: The Breakthrough in Autoimmune Rheumatic Conditions
por: Cavagna, Lorenzo, et al.
Publicado: (2014)

DMARD disruption, disease flare, and prolonged symptom duration after acute COVID-19 among participants with rheumatic disease: A prospective study
por: Di Iorio, Michael, et al.
Publicado: (2022)

Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study
por: Qian, Grace, et al.
Publicado: (2023)

Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
por: Hasseli, Rebecca, et al.
Publicado: (2023)

A Roadmap for Investigating Preclinical Autoimmunity Using Patient-Oriented and Epidemiologic Study Designs: Example of Rheumatoid Arthritis
por: Kowalski, Emily N., et al.
Publicado: (2022)

COVID-19 Outcomes Among Users of CD20 Inhibitors for Immune-Mediated Diseases: A Comparative Cohort Study
por: Patel, Naomi J., et al.
Publicado: (2021)

Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
por: Sieiro Santos, Cristiana, et al.
Publicado: (2022)

Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases
por: Paik, Julie J., et al.
Publicado: (2022)

Does an adjustment to the dosing and timing of immunomodulatory drugs alter the immunogenicity of the COVID-19 vaccines in patients with autoimmune and inflammatory rheumatic disease (AIIRD)?
por: Laster, Andrew J, et al.
Publicado: (2022)

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
por: Andreica, Ioana, et al.
Publicado: (2022)

Coronavirus Disease 2019 Outcomes Among Recipients of Anti‐CD20 Monoclonal Antibodies for Immune‐Mediated Diseases: A Comparative Cohort Study
por: Patel, Naomi J., et al.
Publicado: (2021)

Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors
por: Venerito, Vincenzo, et al.
Publicado: (2022)

Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
por: Sattui, Sebastian Eduardo, et al.
Publicado: (2021)

COVID-19 and Disease-Modifying Anti-rheumatic Drugs
por: D’Silva, Kristin M., et al.
Publicado: (2021)

Incident systemic rheumatic disease following COVID-19
por: Hsu, Tiffany Y-T, et al.
Publicado: (2021)

Exercise, infection and rheumatic diseases: what do we know?
por: Calabrese, Leonard, et al.
Publicado: (2021)

Biological agents for rheumatic diseases in the outbreak of COVID-19: friend or foe?
por: Santos, Cristiana Sieiro, et al.
Publicado: (2021)

Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies
por: Tani, Chiara, et al.
Publicado: (2021)

VACCINATED WITH A TWIST: BREAKTHROUGH COVID-19 IN AN IMMUNOCOMPROMISED PATIENT
por: DAOUD, DANA, et al.
Publicado: (2021)

Predictors of low spike antibody response in patients with systemic rheumatic disease after an initial course of COVID-19 vaccination
por: Whelan, Mary Grace, et al.
Publicado: (2023)

Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study
por: Álvaro Gracia, Jose María, et al.
Publicado: (2021)

Facilitators and barriers of vaccine uptake in patients with autoimune inflammatory rheumatic disease: a scoping review
por: Neusser, Silke, et al.
Publicado: (2022)

Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
por: Andreica, Ioana, et al.
Publicado: (2023)

Maternal and neonatal antibody levels on pertussis vaccination in pregnant women on immune-modulating therapy for rheumatic disease
por: Ghalandari, Nafise, et al.
Publicado: (2023)

Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study
por: Kiltz, Uta, et al.
Publicado: (2021)

Biological treatment usage in patients with HIV and rheumatic disease, 2003–2021: long-term safety and follow-up
por: Naovarat, Benjamin Sornrung, et al.
Publicado: (2022)

Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines
por: Schulze-Koops, Hendrik, et al.
Publicado: (2021)

Efficacy and risk of mRNA vaccination in patients with autoimmune inflammatory rheumatic diseases
por: Kato, Yasuhiro, et al.
Publicado: (2023)

Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases
por: Hasseli, Rebecca, et al.
Publicado: (2021)

Editorial: Breakthroughs in immunotherapies and precision treatment against infectious diseases
por: Huang, Ting, et al.
Publicado: (2022)

Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapies
por: Geisen, Ulf M, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_514asnbrmv8c69ttm2e4lk71s3